Could the functional peptides of sFRP4, in targeting ovarian cancers and their aggressive CSC population, evolve into a promising peptide drug panel for treating highly malignant and drug-resistant ovarian cancer? The gene discussed is SFRP4; the disease is ovarian carcinoma.